FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive Stage SCLC By Ogkologos - October 16, 2025 338 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Outcomes of Cancer Patients with SARS-CoV-2 Infection in Veneto August 20, 2020 ESMO Gynaecological Cancers Congress 2022, 17 – 18 June 2022 Valencia,... June 2, 2022 Can Targeted Therapy for KRAS Mutations Double as Part of Immunotherapy? October 31, 2022 How Fatty Liver Disease Helps Cancer Thrive in the Liver July 6, 2023 Load more HOT NEWS Nivolumab Improves Survival for Some Patients with Advanced Stomach Cancer Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST... Efficacy of Tivozanib Monotherapy in the Post-ICI Setting Among Patients with... Atezolizumab Plus Bevacizumab Approved to Treat Liver Cancer
